Rothschild Asset Management Inc. lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 5.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,436 shares of the biopharmaceutical company’s stock after selling 1,448 shares during the period. Rothschild Asset Management Inc. owned approximately 0.06% of Ultragenyx Pharmaceutical worth $1,704,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Fortaleza Asset Management Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 980 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares during the last quarter. Strs Ohio raised its stake in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares during the period. Ameritas Investment Partners Inc. raised its stake in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 115 shares during the period. Finally, Massmutual Trust Co. FSB ADV bought a new stake in Ultragenyx Pharmaceutical during the first quarter worth about $237,000. 95.71% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) traded down 2.48% on Friday, hitting $56.51. The stock had a trading volume of 263,345 shares. The firm’s market cap is $2.40 billion. Ultragenyx Pharmaceutical Inc. has a one year low of $51.67 and a one year high of $91.35. The company’s 50-day moving average price is $64.40 and its 200 day moving average price is $66.83.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period last year, the company earned ($1.46) earnings per share. Analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.24) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Rothschild Asset Management Inc. Reduces Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/08/19/ultragenyx-pharmaceutical-inc-nasdaqrare-stake-cut-by-rothschild-asset-management-inc-updated.html.
A number of research firms have recently issued reports on RARE. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Sanford C. Bernstein began coverage on Ultragenyx Pharmaceutical in a research report on Thursday, July 27th. They issued a “market perform” rating and a $72.00 price target for the company. Canaccord Genuity set a $98.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Friday, July 28th. ValuEngine upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and a consensus price target of $83.50.
In other news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the sale, the vice president now directly owns 9,366 shares of the company’s stock, valued at approximately $538,170.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.20% of the stock is owned by insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
